970*90
768
468
mobile

Syngene International enters health-linked partnership with Zumutor Biologics

Franchise India Bureau
Franchise India Bureau May 31 2018 - 1 min read
Syngene International enters health-linked partnership with Zumutor Biologics
Under the terms of the agreement, Syngene will screen target antigens against Zumutor's proprietary human antibody libraries to identify and characterize novel antibody clones.

Syngene International, a research company, and Zumutor Biologics, an emerging immuno-oncology company, have entered into a non-exclusive partnering agreement to access Zumutor's proprietary naïve human phage/yeast display library.

This collaboration further enhances Syngene's market-leading capabilities in discovery biology, providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery.

Under the terms of the agreement, Syngene will screen target antigens against Zumutor's proprietary human antibody libraries to identify and characterize novel antibody clones, which will be further developed by Syngene towards novel biotherapeutics programs for its partners.

Kavitha Iyer Rodrigues, Founder-CEO, Zumutor Biologics said, "Zumutor will use its proprietary antibody display platform to enhance Syngene's discovery programmes. Our antibody engineering expertise and experience enables us to optimize any lead to evolve into a best-in-class differentiated molecule".

Commenting on the collaboration, Dr. Manoj Nerurkar, Chief Operating Officer, Syngene International, said, "Syngene has been a pioneer in discovery research and we see Discovery Biology as one of our growth drivers. This partnership will expand our existing portfolio of therapeutic antibody discovery platforms for our clients".

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online